Monitoring of patients receiving eculizumab

Monitoring of patients receiving eculizumab

 

Monitoring of patients receiving Eculizumab treatment is required and the National aHUS Service requires this information to report to NHS England as described in the shared care protocol.

 

  • Monitoring in the early stages of treatment will be based on clinical need and local protocols
  • Testing for evidence of complement blockade by CH100, AH100 (or CH50/AH500) and soluble C5b-9 is recommended during follow-up whilst the patient is receiving Eculizumab.

    • Samples should be sent for monitoring once patients are stable on eculizumab: every 3 months in the first year of treatment and then annually thereafter.

    • Additional samples may be required and will be discussed with the referring consultant on a case-by-case basis.

    • Samples should be sent to the combined aHUS lab diagnostic service

 

  • In stable patients the following tests are recommended on a monthly basis:

    • Renal function

    • Full blood count

    • Lactate dehydrogenase

    • Haptoglobin

    • Urinalysis

    • Urine Protein/Creatinine ratio
  • Monitoring is required for titres following meningococcal vaccination as described in the meningococcal guidance.